H7N9 vaccine production fast-tracked

04/12/2013 | Reuters

Escalating concerns about the H7N9 influenza strain that has surfaced in China have prompted scientists to use new technology to create a viral seed strain, potentially shortening the development time for a vaccine. The approach, developed after the 2009 H1N1 pandemic, uses the genetic code of the virus, instead of a sample of the virus itself, to create synthetic DNA and manufacture the virus then used in vaccine development. The time saved could be critical, said Robin Robinson, director of the Biomedical Advanced Research and Development Authority.

View Full Article in:

Reuters

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Sr. Regulatory Specialist, Biotech Center of Expertise
BASF, The Chemical Co.
San Diego, CA
Food Lawyer
Cargill
Wayzata, MN
Director of Clinical Research
Regenesis Biomedical, Inc.
Scottsdale, AZ
Actuary
Meridian Health Plan
Detroit, MI
Assistant Vice President - Dental Director
MetLife
Bridgewater, NJ